1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date – Oct 01, 2019 Product – Zirabev (biosimilar, bevacizumab) The biosimilar was launched in […]readmore
Tags : ArQule
Shots: Merck to acquire Arqule in all-cash transactions at $20/share, making a total deal value $2.7B. The transaction is expected to be completed in Q1’20 The focus of the acquisition […]readmore